Solara Active Pharma (NSE: SOLARA) – Q1 Investor Briefing

Executive Summary Solara Active Pharma delivered a solid Q1 performance characterized by a 55% year-on-year (YoY) surge in net profit and a 19.7% rise in top-line revenue. While the commodity Ibuprofen segment remains a structural drag on margins, the core base business continues to exhibit robust operational momentum. Management’s active strategic review of underperforming assets and aggressive debt reduction underscore a clear focus on sustainable profitability, which drove a 5% positive market reaction. Financial & Operational Highlights (Q1 ended June 30) Revenue from Operations: ₹382 crore (+19.7% YoY, up from ₹319 crore in Q1 last year). Net Profit: ₹16.3 crore (+55% YoY, up from ₹10.5 crore). EBITDA: ₹62.6 crore (+10% YoY, up from ₹57 crore). EBITDA Margin: Narrowed to 16.4% from 17.8% YoY. This contraction was marginally driven by escalated input costs stemming from ongoing geopolitical developments in West Asia. Segmental Divergence Base Business (Value Driver): The core portfolio generated ₹307.7 crore in revenue (+24% YoY). Despite the aforementioned raw material inflation, gross margins expanded 10% to ₹158 crore, and EBITDA rose 8% to ₹72.2 crore. Commodity Ibuprofen (Margin Drag): The segment continues to heavily weigh on the bottom line, reporting a negative 12% EBITDA margin amid a highly challenging operating environment, though management noted a marginal sequential improvement. Strategic Actions & Capital Allocation Ibuprofen Strategic Review: Management has appointed bankers to evaluate structural and strategic options for the Ibuprofen unit, expecting to finalize next steps by the end of Q2 FY27. Balance Sheet De-leveraging: Net debt was aggressively reduced by ₹134.6 crore during the quarter, dropping the total to ₹479.5 crore and optimizing the annualized net debt-to-EBITDA ratio to approximately 1.9x.